11C-UCB-J

Last updated
11C-UCB-J
11C-UCB-J.svg
Names
Preferred IUPAC name
(4R)-1-{[3-(11C)Methylpyridin-4-yl]methyl}-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one
Other names
[11C]UCB-J; 11C-UCB-J; [11C]UCB-J
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C17H15F3N2O/c1-10-7-21-3-2-11(10)8-22-9-13(6-16(22)23)12-4-14(18)17(20)15(19)5-12/h2-5,7,13H,6,8-9H2,1H3/t13-/m0/s1/i1-1
    Key: RFSDYRVOGWHOFT-XOTOJZTHSA-N
  • [11CH3]C1=CN=CC=C1CN1C[C@H](CC1=O)C1=CC(F)=C(F)C(F)=C1
Properties
C17H15F3N2O
Molar mass 320.315 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

11C-UCB-J is a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the human brain. [1]

It is used to study the brain changes associated with several diseases including Alzheimer's disease, [2] [3] schizophrenia, [4] [5] and depression. [6]

References

  1. ↑ Nabulsi, NB; Mercier, J; Holden, D; Carré, S; Najafzadeh, S; Vandergeten, MC; Lin, SF; Deo, A; Price, N; Wood, M; Lara-Jaime, T; Montel, F; Laruelle, M; Carson, RE; Hannestad, J; Huang, Y (2016). "Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain". J Nucl Med. 57 (5): 777–84. doi: 10.2967/jnumed.115.168179 . PMID   26848175.
  2. ↑ Toyonaga, Takuya; Smith, Levi M.; Finnema, Sjoerd J.; Gallezot, Jean-Dominique; Naganawa, Mika; Bini, Jason; Mulnix, Tim; Cai, Zhengxin; Ropchan, Jim; Huang, Yiyun; Strittmatter, Stephen M.; Carson, Richard E. (2019). "In vivo synaptic density imaging with 11C-UCB-J detects treatment effects of saracatinib (AZD0530) in a mouse model of Alzheimer's disease". Journal of Nuclear Medicine. 60 (12): 1780–1786. doi: 10.2967/jnumed.118.223867 . PMC   6894376 . PMID   31101744.
  3. ↑ Márquez, Freddie; Yassa, Michael A. (2019). "Neuroimaging Biomarkers for Alzheimer's Disease". Molecular Neurodegeneration. 14 (1): 21. doi: 10.1186/s13024-019-0325-5 . PMC   6555939 . PMID   31174557.
  4. ↑ Onwordi, Ellis Chika; Halff, Els F.; Whitehurst, Thomas; Mansur, Ayla; Cotel, Marie-Caroline; Wells, Lisa; Creeney, Hannah; Bonsall, David; Rogdaki, Maria; Shatalina, Ekaterina; Reis Marques, Tiago; Rabiner, Eugenii A.; Gunn, Roger N.; Natesan, Sridhar; Vernon, Anthony C.; Howes, Oliver D. (14 January 2020). "Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats". Nature Communications. 11 (1): 246. Bibcode:2020NatCo..11..246O. doi: 10.1038/s41467-019-14122-0 . ISSN   2041-1723. PMC   6959348 . PMID   31937764.
  5. ↑ Radhakrishnan, Rajiv; Skosnik, Patrick; Finnema, Sjoerd; Rotolo, Renee; Forselius-Bielen, Kimberlee; Creatura, Gina; Nabulsi, Nabeel; Carson, Richard; d׳Souza, Deepak (2017). "962. In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging Study". Biological Psychiatry. 81 (10): S389. doi:10.1016/j.biopsych.2017.02.688. S2CID   54259458.
  6. ↑ Holmes, Sophie E.; Scheinost, Dustin; Finnema, Sjoerd J.; Naganawa, Mika; Davis, Margaret T.; Dellagioia, Nicole; Nabulsi, Nabeel; Matuskey, David; Angarita, Gustavo A.; Pietrzak, Robert H.; Duman, Ronald S.; Sanacora, Gerard; Krystal, John H.; Carson, Richard E.; Esterlis, Irina (2019). "Lower synaptic density is associated with depression severity and network alterations". Nature Communications. 10 (1): 1529. Bibcode:2019NatCo..10.1529H. doi:10.1038/s41467-019-09562-7. PMC   6449365 . PMID   30948709.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.